BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

February 27, 2013

WALTHAM, Mass., Feb 27, 2013 (Menafn - GLOBE NEWSWIRE via COMTEX) --BG Medicine, Inc. BGMD, a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today the publication of two studies demonstrating the clinical utility of repeated galectin-3 testing as a tool in the assessment of patients with heart failure.

Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate

Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate

February 26, 2013

DUBLIN and LEXINGTON, Mass., Feb 26, 2013 (BUSINESS WIRE) -- Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. today announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.

Seahorse Bioscience XF Technology Yields Insights on Leukemia Stem Cell Metabolism and Potential New Leukemia Therapies

Seahorse Bioscience XF Technology Yields Insights on Leukemia Stem Cell Metabolism and Potential New Leukemia Therapies

February 22, 2013

500th XF Data Reference in Elsevier: Cell Stem Cell

Billerica, MA, February 22, 2013 – Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism, announced a new milestone: the 500th journal reference including XF assay data. The paper, titled BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells, will be published in the March 7, 2013 issue of the journal Cell Stem Cell.

Novomer Completes World’s First Large-Scale PPC Polyol Manufacturing Run

Novomer Completes World’s First Large-Scale PPC Polyol Manufacturing Run

February 20, 2013

WALTHAM, MA – February 20, 2013 – Novomer, Inc., a sustainable materials company pioneering a family of high-performance polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), has announced the world's first large-scale manufacturing run of polypropylene carbonate (PPC) polyol, producing over seven tons of finished product. The PPC polyol was scaled up and produced with Albemarle at their Orangeburg, South Carolina manufacturing facility using existing Albemarle equipment, which was modified for PPC polyol production.

Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease

Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease

February 19, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease

Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease

February 19, 2013

Ensemble Therapeutics Presents Data Demonstrating Unique Properties of Synthetic Macrocycles for Pursuing Challenging Targets

Ensemble Therapeutics Presents Data Demonstrating Unique Properties of Synthetic Macrocycles for Pursuing Challenging Targets

February 13, 2013

Preclinical Data Showing Benefits of Macrocycle Discovery Platform in Identifying First-in-Class Oral IL-17 Antagonists Presented At Molecular Med Tri Con 2013 Conference

Graham Cooper Appointed Chief Financial Officer of Receptos

Graham Cooper Appointed Chief Financial Officer of Receptos

February 14, 2013

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Receptos, Inc. announced today that Graham Cooper has been appointed Chief Financial Officer. Mr.

Tetraphase Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

Tetraphase Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

February 12, 2013

Watertown, MA – February 12, 2013 – Tetraphase Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering.

Concert Pharmaceuticals Announces Milestone Achievement in Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Announces Milestone Achievement in Avanir Pharmaceuticals Collaboration

February 7, 2013

LEXINGTON, Mass.--()--Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone under its licensing agreement with Avanir Pharmaceuticals, Inc. for the development of AVP-786 (also known as CTP-786 or deuterated dextromethorphan).